Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17537229 | 0.73 | KDM4E (0.48) | KDM4ELMNAL3MBTL1PDE4ATDP1 | |
| SCHEMBL875592 | 0.73 | PDE4A (0.54) | KDM4ELMNAL3MBTL1PDE4ATDP1 | |
| SCHEMBL9169459 | 0.72 | KDM4E (0.40) | KDM4ELMNAL3MBTL1PDE4ATDP1 | |
| SCHEMBL13010838 | 0.72 | KDM4E (0.47) | KDM4ELMNAL3MBTL1PDE4ATDP1 | |
| SCHEMBL13010836 | 0.72 | KDM4E (0.47) | KDM4ELMNAL3MBTL1PDE4ATDP1 | |
| Mannitol SCHEMBL3017327 | 0.63 | LMNA (0.69) | KDM4ELMNAL3MBTL1PDE4ATDP1 | |
| Mannitol SCHEMBL7927609 | 0.63 | LMNA (0.69) | KDM4ELMNAL3MBTL1PDE4ATDP1 | |
| Mannitol SCHEMBL8472459 | 0.63 | LMNA (0.69) | KDM4ELMNAL3MBTL1PDE4ATDP1 | |
| Mannitol SCHEMBL11031577 | 0.63 | LMNA (0.69) | KDM4ELMNAL3MBTL1PDE4ATDP1 | |
| Sorbitol SCHEMBL29468856 | 0.63 | LMNA (0.69) | KDM4ELMNAL3MBTL1PDE4ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560230-B2 | Method for determining susceptibility of tumor to treatment with anti-neoplastic agent | THRESHOLD PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20060172305-A1 | Method for determining susceptibility of tumor to treatment with anti-neoplastic agent | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2006-08-03 | — | — | US | disclosed |